These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 37448966)

  • 1. Dalbavancin as suppressive antibiotic therapy in patients with prosthetic infections: efficacy and safety.
    Ruiz-Sancho A; Núñez-Núñez M; Castelo-Corral L; Martínez-Marcos FJ; Lois-Martínez N; Abdul-Aziz MH; Vinuesa-García D
    Front Pharmacol; 2023; 14():1185602. PubMed ID: 37448966
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Experience with dalbavancin use in various gram-positive infections within Aberdeen Royal Infirmary OPAT service.
    McSorley JC; Reyes D; Tonna I; Bateman V
    Infection; 2024 Apr; 52(2):567-576. PubMed ID: 38165594
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dalbavancin real-life utilization among diabetic patients suffering from infections in Italy and Spain: The DALBADIA retrospective cohort study.
    Morata Ruiz L; Ruggieri A; Falcone M; Pasquau Liaño J; Gentile I; Salavert Lletí M; Moreno Núñez L; Cascio A; Tascini C; Loeches Yagüe M; De Rosa FG; Ori A; Comandini A; Cattaneo A; Grossi PA;
    J Glob Antimicrob Resist; 2024 Mar; 36():200-209. PubMed ID: 38211660
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dalbavancin as an alternative to traditional outpatient parenteral antimicrobial therapy for deep gram-positive infections - an observational, retrospective review.
    Bao H; Igwilo-Alaneme R; Sonia F; Cowman K; Kahn M; Nori P
    Ther Adv Infect Dis; 2024; 11():20499361241245523. PubMed ID: 38645297
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dalbavancin as sequential therapy in infective endocarditis: Real-life experience in elder and comorbid patients.
    Aparicio-Minguijón E; Boán J; Terrón A; Heredia C; Puente C; Pérez-Jacoiste Asín A; Orellana MÁ; Domínguez L; Caro JM; López-Gude MJ; Aguilar-Blanco EM; Eixerés-Esteve A; López-Medrano F
    Enferm Infecc Microbiol Clin (Engl Ed); 2024 Jun; ():. PubMed ID: 38902152
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chronic antibiotic suppressive therapy with dalbavancin: a case series.
    Pallotto C; Tommasi A; Albagini M; Genga G; Svizzeretto E; Gidari A; Tordi S; Francisci D
    J Chemother; 2024 May; ():1-5. PubMed ID: 38712995
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Off-label use of dalbavancin in children: a case series.
    Gamell A; Velasco-Arnaiz E; López-Ramos MG; Ríos-Barnés M; Simó-Nebot S; Fumadó V; Noguera-Julián A; Fortuny C
    J Antimicrob Chemother; 2024 Jul; ():. PubMed ID: 38958260
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dalbavancin Sequential Therapy for Gram-Positive Bloodstream Infection: A Multicenter Observational Study.
    Rebold N; Alosaimy S; Pearson JC; Dionne B; Taqi A; Lagnf A; Lucas K; Biagi M; Lombardo N; Eudy J; Anderson DT; Mahoney MV; Kufel WD; D'Antonio JA; Jones BM; Frens JJ; Baumeister T; Geriak M; Sakoulas G; Farmakiotis D; Delaportas D; Larew J; Veve MP; Rybak MJ
    Infect Dis Ther; 2024 Mar; 13(3):565-579. PubMed ID: 38427289
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term Oral Suppressive Antimicrobial Therapy in Infective Endocarditis (SATIE Study): An Observational Study.
    Beaumont AL; Mestre F; Decaux S; Bertin C; Duval X; Iung B; Rouzet F; Grall N; Para M; Thy M; Deconinck L
    Open Forum Infect Dis; 2024 May; 11(5):ofae194. PubMed ID: 38737431
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-life experience with IV dalbavancin in Canada; results from the CLEAR (Canadian LEadership on Antimicrobial Real-life usage) registry.
    Zhanel G; Silverman M; Malhotra J; Baxter M; Rahimi R; Irfan N; Girouard G; Dhami R; Kucey M; Stankus V; Schmidt K; Poulin S; Connors W; Tascini C; Walkty A; Karlowsky J
    J Glob Antimicrob Resist; 2024 Jun; 38():154-157. PubMed ID: 38908823
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dalbavancin for the treatment of bone and joint infections: a meta-analysis.
    Almangour TA; Alrasheed M
    J Infect Chemother; 2024 Jul; ():. PubMed ID: 39029624
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Three-years of dalbavancin use at a UK tertiary referral hospital serving a population with high numbers of people who inject drugs.
    Bresges C; Bresges K; Hewitt C; Sharma S; Davies B
    JAC Antimicrob Resist; 2024 Jun; 6(3):dlae066. PubMed ID: 38716401
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dosing and treatment duration of suppressive antimicrobial therapy in orthopedic implant infections: a cohort study.
    Hanssen JLJ; van der Wal RJP; van der Linden HMJ; van Prehn J; Scheper H; de Boer MGJ
    J Bone Jt Infect; 2024; 9(3):149-159. PubMed ID: 38903857
    [No Abstract]   [Full Text] [Related]  

  • 14. The use of long-term antibiotics for suppression of bacterial infections.
    Horne M; Woolley I; Lau JSY
    Clin Infect Dis; 2024 Jun; ():. PubMed ID: 38832929
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness and safety of dalbavancin in France: a prospective, multicentre cohort study.
    Courjon J; Senneville E; Illes HG; Pavese P; Boutoille D; Daoud FC; Dunkel N; Tattevin P
    Int J Antimicrob Agents; 2023 Oct; 62(4):106945. PubMed ID: 37543122
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Dalbavancin is an antimicrobial to consider in prosthetic orthopedic infections caused by Staphylococcus].
    Sánchez Ortiz M; Linge Martín M; González Eizaguirre MM
    Rev Esp Geriatr Gerontol; 2023; 58(5):101378. PubMed ID: 37450983
    [No Abstract]   [Full Text] [Related]  

  • 17. Dalbavancin as suppressive therapy for implant-related infections: a case series with therapeutic drug monitoring and review of the literature.
    Lafon-Desmurs B; Gachet B; Hennart B; Valentin B; Roosen G; Degrendel M; Loiez C; Beltrand E; D'Elia P; Migaud H; Robineau O; Senneville E
    Eur J Clin Microbiol Infect Dis; 2024 Jul; 43(7):1475-1480. PubMed ID: 38753112
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New Frontier on Antimicrobial Therapy: Long-Acting Lipoglycopeptides.
    Siciliano V; Sangiorgi F; Del Vecchio P; Vahedi L; Gross MM; Saviano A; Ojetti V
    Pathogens; 2024 Feb; 13(3):. PubMed ID: 38535533
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic Drug Monitoring of Dalbavancin in Real Life: A Two-Year Experience.
    Cattaneo D; Fusi M; Colaneri M; Fusetti C; Genovese C; Giorgi R; Matone M; Merli S; Petri F; Gori A
    Antibiotics (Basel); 2023 Dec; 13(1):. PubMed ID: 38247579
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.